BioSpace News Archive

The U.S. Food and Drug Administration granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Sasakawa Health Foundation has announced the start of its first-ever social media campaign with organizations of persons affected by leprosy.

Austin Regional Clinic is partnering with Cognoa, a leading pediatric behavioral health company, on a national multi-site clinical trial to test the performance of a new diagnostic device for autism spectrum disorder.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced the pricing of its public offering of 2,741,489 shares of its common stock, par value $0.0001 per share, at a price to the public of $45.50 per share.

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on January 23, 2020.

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced the appointment of David E. Moller, MD, as Chief Scientific Officer.

Oxford Immunotec Global PLC, a global, high-growth diagnostics company, announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the benefits of the T-SPOT®.TB test to mainland China and assist with differentiating tuberculosis from other respiratory infections.

Novacap, founders, and management shareholders will reinvest alongside new partner

Transaction will reinforce Hg’s focus on healthcare technology, with over $1bn invested to date in the sector globally;

Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it has completed principle design work for a PCR screening test for new coronavirus, 2019-nCoV, intended to address potential need for detection of the virus.